PMID: 19132191Jan 10, 2009Paper

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

Thrombosis and Haemostasis
Alexander G G TurpieEXPERT Study Group

Abstract

Betrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of venous thromboembolism (VTE). Its antithrombotic effects had not been previously tested in patients. This exploratory clinical trial in the US and Canada randomized 215 patients undergoing elective total knee replacement (TKR) in a 2:2:1 ratio to receive post-operative betrixaban 15 mg or 40 mg p.o. bid or enoxaparin 30 mg s.c. q12h, respectively, for 10-14 days. The betrixaban dosage was blinded, but enoxaparin was not. Primary efficacy outcome was the incidence of VTE, consisting of deep-vein thrombosis (DVT) on mandatory unilateral (operated leg) venography, symptomatic proximal DVT, or pulmonary embolism (PE) through Day 10-14. Safety outcomes included major and clinically significant non-major bleeds through 48 h after treatment. All efficacy and bleeding outcomes were adjudicated by a blinded independent central adjudication committee. Of 214 treated patients, 175 (82%) were evaluable for primary efficacy. VTE incidence was 14/70 (20%; 95% CI: 11, 31) for betrixaban 15 mg, 10/65 (15%; 95% CI: 8, 27) for betrixaban 40 mg, and 4/40 (10%; 95% CI: 3, 24) for enoxaparin. No bleeds were reported for betrixaban 15 mg, 2 (2.4%) clinica...Continue Reading

Citations

Aug 6, 2011·QJM : Monthly Journal of the Association of Physicians·J Kreuzer
Jun 10, 2010·Drug Design, Development and Therapy·Cecilia BecattiniGiancarlo Agnelli
May 16, 2013·Vascular Health and Risk Management·Antonio Gómez-OutesEduardo Rocha
Aug 27, 2009·Vascular Health and Risk Management·Andrew D Blann, Chee W Khoo
Nov 23, 2010·Journal of Atherosclerosis and Thrombosis·Selvakumar Velu, Gregory Y H Lip
Apr 13, 2012·Advances in Hematology·Roberto C Montoya, Ajeet Gajra
Feb 15, 2018·Journal of Clinical Medicine·Stephanie A JoppaFadi Shamoun
Mar 10, 2011·Expert Opinion on Investigational Drugs·Erica Romualdi, Walter Ageno
Oct 26, 2018·Future Cardiology·Katelyn W Sylvester, Jean M Connors
Jan 8, 2019·Expert Opinion on Pharmacotherapy·Daniele ScarpaVittorio Pengo
Jun 27, 2018·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jona Lekura, James S Kalus
Oct 20, 2009·Journal of Thrombosis and Thrombolysis·Meyer Michel Samama, Grigoris T Gerotziafas
Feb 28, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Tara L Knotts, Shaker A Mousa
Jun 4, 2010·Current Opinion in Cardiology·Jonathan P PicciniKenneth W Mahaffey
Oct 23, 2010·Drugs·Hans-Juergen Rupprecht, Ralf Blank
Apr 4, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Tigran KhachatryanAnthony Hilliard
Jun 18, 2010·Cardiovascular Therapeutics·Stavros ApostolakisEduard Shantsila
Jun 1, 2011·Therapeutic Advances in Hematology·Iwona RybakJohn Fanikos
May 7, 2011·British Journal of Clinical Pharmacology·Vincenzo Toschi, Maddalena Lettino
Jul 12, 2011·British Journal of Pharmacology·Job HarenbergMartin Wehling
Jan 6, 2012·The Journal of Bone and Joint Surgery. American Volume·Young-Kyun LeeMoon Seok Park
Jan 25, 2012·Journal of Burn Care & Research : Official Publication of the American Burn Association·Indermohan ThethiJawed Fareed
Sep 7, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jacob I Haft
Jul 16, 2013·Current Opinion in Hematology·Shari Ghanny, Mark Crowther
Jul 24, 2013·Expert Opinion on Investigational Drugs·Gentian Denas, Vittorio Pengo
Aug 24, 2013·Expert Opinion on Investigational Drugs·Michael PalladinoLynda Thomson
Dec 19, 2013·Future Cardiology·Noel C ChanJohn W Eikelboom
Mar 1, 2012·Cardiology in Review·Abhishek MaanE Kevin Heist
May 13, 2010·American Journal of Therapeutics·Dhara ChaudhariRohit Arora
Jul 16, 2010·Cardiovascular Therapeutics·Job Harenberg, Martin Wehling
Jan 14, 2011·Expert Opinion on Emerging Drugs·Tarek A N AhmedJ Wouter Jukema
Aug 9, 2011·Annual Review of Pharmacology and Toxicology·Jawed FareedDebra Hoppensteadt
Mar 1, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Sorrel E Wolowacz
Mar 1, 2011·Expert Opinion on Emerging Drugs·Gentian Denas, Vittorio Pengo
Dec 8, 2009·Medicinal Research Reviews·Yu-Kai Lee, Mark R Player
Sep 29, 2011·Pharmacotherapy·Estella M DavisJennifer A Campbell
Feb 22, 2012·Nature Reviews. Cardiology·James W Wisler, Richard C Becker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.